-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653.O1.3 653. Myeloma: Therapy, excluding Transplantation: Amyloidosis and Related Plasma Cell Disorders

Myeloma: Therapy, excluding Transplantation Program: Oral and Poster Abstracts
Type: Oral
Sunday, December 6, 2015: 7:30 AM-9:00 AM
Tangerine 2 (WF2), Level 2 (Orange County Convention Center)
Moderators:
Morie A Gertz, MD, Mayo Clinic and Ajay K Nooka, MD MPH, Emory University

Disclosures:
No relevant conflicts of interest to declare.
7:30 AM

Jatin J. Shah, MD1, Lei Feng, MS2*, Elisabet E. Manasanch, MD1, Donna Weber, MD1, Sheeba K Thomas, MD1, Francesco Turturro, MD1, Nina Shah, MD3, Uday R. Popat, MD4, Yago Nieto, MD, PhD3, Qaiser Bashir, MD3, Silvia C Munoz, RN1*, Ashley Landry, RN1*, Kathleen Mendoza, RN1*, Richard E. Champlin, MD3, Muzaffar H. Qazilbash, MD3 and Robert Z. Orlowski, Ph.D., M.D.5

1Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
4Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

7:45 AM

Arielle L Langer, MD, MPH1*, Susanna Miao2*, Markus Mapara, MD, PhD3, Jai Radhakrishnan, MD4*, Mathew S. Maurer, MD5*, Shahzad Raza, MD6*, John G. Mears, MD3, Alan Solomon, MD7 and Suzanne Lentzsch, MD, PhD3

1Dept of Medicine, Columbia University, New York, NY
2College of Medicine, Drexel University, Philadelphia
3Division of Hematology/Oncology, Columbia University, New York, NY
4Division of Nephrology, Columbia University, New York
5Division of Cardiology, Columbia University, New York, NY
6Division of Hematology/Oncology, Columbia University Medical Center, New York, NY
7Graduate School of Medicine, University of Tennessee, Knoxville, TN

8:00 AM

Charlotte Pawlyn, MB BChir1,2*, Faith E Davies, MD2,3, David A Cairns4*, Corinne Collett4*, Anna Chalmers4*, Alina Striha4*, John R Jones, MD1,2*, Mamta Garg, MD5*, David Allotey, MD6*, Kamaraj Karunanithi, MBBS, MD7*, Donald Milligan, MD, MBChB8, Martin F Kaiser, MD1,2*, Matthew W Jenner, MD9*, Gordon Cook, MD, PhD10, Nigel H. Russell, MD11, Mark T Drayson, MD, PhD12*, Roger G Owen, MD13, Walter M Gregory4*, Graham H Jackson, MD14 and Gareth J Morgan, MD, PhD2,3

1Department of Haematology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
2The Institute of Cancer Research, London, United Kingdom
3Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
4Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
5Leicester Royal Infirmary, Leicester, United Kingdom
6Royal Derby Hospital, Derby, United Kingdom
7University Hospital of North Midlands, Stoke-on-Trent, United Kingdom
8Heart of England NHS Foundation Trust, Birmingham, United Kingdom
9Southampton General Hospital, Southampton, United Kingdom
10University of Leeds, Leeds, United Kingdom
11Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom
12Clinical Immunology, School of Immunity & Infection, University of Birmingham, Birmingham, United Kingdom
13St. James's University Hospital, Leeds, United Kingdom
14Department of Haematology, University of Newcastle, Newcastle-upon-Tyne, United Kingdom

8:15 AM

Giovanni Palladini, MD, PhD1, Paolo Milani, MD2*, Eloisa Riva, MD3, Marco Basset, MD2*, Andrea Foli, MD2* and Giampaolo Merlini, MD1

1Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Department of Molecular Medicine, Pavia, Italy
2Amyloidosis Research and Treatment Center, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
3Hematology Department, Hospital De Cli­nicas, Montevideo, Uruguay

8:30 AM

Herve Avet-Loiseau, MD, PhD1*, Jill Corre2*, Valerie Lauwers-Cances, MD3*, Marie-Lorraine Chretien4*, Nelly Robillard, Engineer5*, Xavier Leleu, MD, PhD6, Cyrille Hulin, MD7*, Catherine Gentil, Engineer8*, Bertrand Arnulf9*, Karim Belhadj, MD10*, Sabine Brechignac, MD11*, Laurent Garderet, MD12, Lionel Karlin13*, Gerald Marit14*, Lotfi Benboubker15*, Frederique Orsini-Piocelle, MD16*, Bruno Royer, MD17,18*, Bernard Drenou, MD19*, Mourad Tiab, MD20*, Thierry Lamy, MD, PhD21, Margaret MACRO, MD22*, Paul G. Richardson, MD23, Kenneth C Anderson, MD24, Malek Faham, MD, PhD25, Thierry Facon26, Philippe Moreau27,28,29*, Michel Attal30 and Nikhil C. Munshi, MD31

1Unit for Genomics in Myeloma, Institut Universitaire du Cancer, Toulouse, France
2Institut Universitaire du Cancer, Toulouse, France
3CHU Toulouse, Toulouse, France
4Service Hematologie, CHU Dijon, Dijon, France
5CHU, Nantes, France
6Service des Maladies du Sang, Hopital Huriez, CHRU, Lille, France
7CHRU Hopitaux de Brabois, NANCY CEDEX, France
8CHU, Toulouse, France
9Hôpital Saint Louis, Paris, France
10CHU Henri Mondor, Creteil, France
11Hopital Avicenne, bobigny, France
12Hôpital Saint Antoine, Paris, France
13Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France
14CHU, Bordeaux, France
15CHU, Tours, France
16CHD, Annecy, France
17CHU, Amiens, France
18Hematology, Centre Hospitalier Universitaire, Amiens, France
19CH MULHOUSE, MULHOUSE, France
20Hopital la Roche Sur Yon, La Roche Sur Yon Cedex 9, France
21Haematology, CHU Pontchaillou, Rennes, France
22Hopital Cote De Nacre, Caen Cedex 9, France
23Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
24The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
25Adaptive Biotechnologies, South San Francisco, CA
26Maladies du Sang, Hôpital Claude Huriez, CHRU Lille, Lille, France
27Hopital Hotel Dieu Et Hme, Nantes Cedex 1, France
28Nantes University Hospital, Hôtel‐Dieu, Nantes, France
29chu, NANTES, France
30Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
31Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA

8:45 AM

Jian Li, MD1*, Qian-qian Cai, MD2*, Chen Wang, MD2*, Xin-xin Cao, MD2* and Dao-bin Zhou, MD1*

1Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
2Hematology department, Peking Union Medical College Hospital, Beijing, China

*signifies non-member of ASH